Physician profile
Hal M Corwin
NPI 1124005319
$20,444.73
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2021: $12.65.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $18,718.61 | 2019 | |
| Sunovion Pharmaceuticals INC. | $815.17 | 2019-2021 | |
| Ucb, INC. | $192.94 | 2019 | |
| Allergan, INC. | $187.79 | 2019 | |
| Supernus Pharmaceuticals, INC. | $184.89 | 2019 | |
| Eisai INC. | $135.71 | 2019 | |
| Lilly USA, LLC | $50.83 | 2019 | |
| Kyowa Kirin, INC. | $33.28 | 2019 | |
| Novartis Pharmaceuticals Corporation | $28.09 | 2019 | |
| Mdd US Operations, LLC | $20.24 | 2019 | |
| Amgen INC. | $19.63 | 2019 | |
| Endo Pharmaceuticals INC. | $18.42 | 2019 | |
| Arbor Pharmaceuticals, INC. | $15.79 | 2019 | |
| Zyla Life Sciences, INC. | $11.73 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Corwin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.